Device Trial Radar · NCT04629157
The LAVA (Lateral Flow Antigen Validation and Applicability) Study for COVID-19
Last checked: Nov 20, 2026Latest source record: Nov 13, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
400
Actual
Start
Nov 5, 2020
Primary completion
Feb 1, 2021
Study completion Feb 1, 2021
Sponsor
- Lead sponsor
- Alder Hey Children's NHS Foundation TrustAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Nov 16, 2020
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Diagnostic
- FDA-regulated device
- No
- Who can join
- All sexes, from 0 years, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a pilot study which aims to assess the validity and applicability of lateral flow assays (LFAs) which can be used as a point of care test for COVID-19. The study will focus on children admitted to hospital or planned to have a procedure for which they require an anaesthetic. RT-PCR is the current gold standard test for COVID-19, but it usually takes approximately 24-48 hours for a test result to be returned which can slow the clinical care given to a patient and can potentially increase the risk of healthcare worker (HWC) exposure to COVID-19. LFAs are a point of care test which can identify children who have a high viral load of COVID-19 and are performed using a more acceptable method of swabbing for children, just inside the nostril. Using LFA potentially enables the identification of infectious children with COVID-19 to aid with immediate care of patients and limiting HWC and other patients' contact with the virus. This study aims to assess the test failure rate and identify reasons for this which can be addressed. It also aims to assess the discomfort of both tests for children, provide a comparison between the time to LCA and RT-PCR result and provide data for a trial to adequately power a prospective trial comparing RT-PCR and LFA.
Conditions
- This is a Pilot Study Which Aims to Assess the Validity and Applicability of Lateral Flow Assays (LFAs) Which Can be Used as a Point of Care Test for COVID-19
- Covid19
Interventions
Innova Lateral Flow DeviceDevice
The Innova Lateral Flow Device will be used on anterior nasal swab specimens and RT-PCR will be performed on nose and throat swabs.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Acceptability of TestTime frame: Immediately after test on the day of test
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Alder Hey in the Park
Liverpool, United Kingdom
1 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.